Watermark Medical, Inc.
$9.7K 534 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pyros Pharmaceuticals, Inc.
Pyros Pharmaceuticals, Inc. reported $9,689.65 across General Payments, Research, and Ownership to 260 physicians and teaching hospitals across 260 transactions.
- $9.7K Below-median payer
- All-tracks total
- 260 Above-median volume
- Transactions
- 260 Above-median reach
- Recipients
- +$3.6K
- General Payments vs PY2023
Pyros Pharmaceuticals, Inc. reported $9,689.65 across all CMS Open Payments tracks (General + Research + Ownership) to 260 physicians and teaching hospitals in Program Year 2024 - ranking #1648 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $9,689.65, averaging $37.27 per recipient.
Pyros Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
11/100
Total payments
F
10/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pyros-pharmaceuticals-inc Pyros Pharmaceuticals, Inc.
$9.7K · #1648/1,925 · 0.0% industry · PY2024
- TOT $9.7K
- RANK #1648
- SHARE 0.0%
- TXN 260
- RCP 260
- CAT 1
- GEN $9.7K
- ΔGEN +$3.6K
- TOP1 5.0%
- PY 2024
Volume peers
Nearest volume peer: Watermark Medical, Inc. ($9.7K)
Pyros Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pyros Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $3.6K (+58.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: PYROS PHARMACEUTICALS, INC.PY2024: Pyros Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,132.39
- PY2024
- $9,689.65
What the Data Shows for Pyros Pharmaceuticals, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Pyros Pharmaceuticals, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Food and Beverage" leads the 1-category general-payment breakdown below at $9.7K (100.0% of General Payments, 260 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Pyros Pharmaceuticals, Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $9.7K, 100.0% of General Payments.
How Pyros Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $9.7K | 260 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,338.97 (13.8%) of $9,689.65 in this company's General Payments records across 179 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pyros Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Osman Farooq
$482.01 across 2 reported transactions
- 2
Jennifer Mcvige
$233.45 across 2 reported transactions
- 3
Beck Leslie Espiritu
$208.31 across 3 reported transactions
- 4
Aran Groves
$208.31 across 3 reported transactions
- 5
Khalid Kakish
$206.89 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pyros Pharmaceuticals, Inc.'s spend rank (#1648 of 1,925, bottom 14% by spend) and concentration rank (#1,668 of 1,838, bottom 9% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Corcept Therapeutics : $3.9M total payments, HHI 117
- Orthofix Medical, Inc. : $9.6M total payments, HHI 116
- Exact Sciences Corporation : $3.5M total payments, HHI 115
- BIOTRONIK NRO, Inc. : $814.5K total payments, HHI 114
- New World Medical,inc. : $334.1K total payments, HHI 114
- Sobi, Inc : $3.4M total payments, HHI 114
- Pyros Pharmaceuticals, Inc. (this company) : $9.7K total payments, HHI 114
- Oyster Point Pharma, Inc. : $1.1M total payments, HHI 113
- ImpactOrtho, Inc. : $52.7K total payments, HHI 113
- Glaukos Corporation : $3.6M total payments, HHI 112
- Southern Anesthesia & Surgical, Inc (dba Ace Southern) : $3.8K total payments, HHI 112
- Actelion Pharmaceuticals US, Inc. : $5.0M total payments, HHI 112
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pyros Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pyros Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pyros Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
CMF Medicon Surgical Inc.
$9.8K 7 recipients
Compare payment profiles
Greer Laboratories, Inc.
$9.8K 413 recipients
Compare payment profiles
Streck LLC
$9.8K 23 recipients
Compare payment profiles
Oak Med, Inc.
$9.5K 106 recipients
Compare payment profiles
Uresil LLC
$9.9K 4 recipients
Compare payment profiles
Put this to use
Pyros Pharmaceuticals, Inc. ranks #1648 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Pyros Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.